The Global Endometriosis Treatment Industry, valued at a substantial US$ 2.8 billion in 2018, is gearing up for a remarkable expansion with a projected Compound Annual Growth Rate (CAGR) of around 3% over the period 2019-2030. This surge is attributed to the rising awareness among women about endometriosis and substantial investments by key stakeholders in the healthcare sector.
The prevalence of endometriosis is on the rise, prompting an increased demand for advanced treatment options. Industry leaders are at the forefront of this movement, concentrating on pioneering therapeutic advancements and launching innovative products that are poised to catalyze future market growth.
Request a Sample Copy of This Report Now.
https://www.futuremarketinsights.com/reports/sample/rep-gb-3870
Key Takeaways of Global Endometriosis Treatment Industry Study
- Based on the drug, oral contraceptives contributed maximum value share to the global endometriosis treatment Industry in 2018, owing to a high preference for them as a first-line therapy for patients without contraindications, and efficacy in preventing the recurrence of pelvic pain and endometriosis lesions.
- High treatment efficacy and acceptance with low risk are expected to result in a notable share of hormonal therapy in the treatment type.
- The hospital pharmacies and retail pharmacies segments, collectively, hold above 60% of the value share in the endometriosis treatment industry, owing to the high patient pool in hospitals and visiting retail pharmacies.
- Europe captured a notable revenue share of 37% in 2018 and is expected to be the most lucrative region in the Global Endometriosis Treatment Industry during the forecast period.
- Increasing government expenditure for the high growth of the medical industry in emerging economies in the Asian region is expected to drive the growth of the endometriosis treatment industry across this region.
Multiple New Indications – Imperative Strategy for Market Players
Increasing the introduction of endometriosis drugs with multiple new indications is a major factor responsible for intense competition among market players. Several companies are focusing on launching new endometriosis treatment options to increase their product sales and expand their market share. For example, in July 2018, AbbVie Inc. introduced a new innovative product – Orilissa (elagolix) tablets, a gonadotropin-releasing hormone (GnRH) receptor antagonist for the management of moderate to severe pain associated with endometriosis, in the U.S. market.
Methodology Details Just a Click Away!
https://www.futuremarketinsights.com/request-report-methodology/rep-gb-3870
What else is in the report?
Future Market Insights (FMI) offers a unique perspective and actionable insights on the endometriosis treatment market in its latest study, presenting a historical demand assessment of 2014-2018 and projections for the period of 2019-2030, based on the drug (oral contraceptives, progestins, NSAIDs, GnRH analogs, LNR-IUDs, and others), treatment type (hormonal therapy and pain management), and distribution channel (hospital pharmacies, retail pharmacies, drugstores, and e-Commerce), across seven key regions of the world.
Global Endometriosis Treatment Industry segmentation
The global endometriosis treatment industry is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader.
Drug:
- Oral Contraceptives
- Progestins
- NSAIDs
- GnRH Analogues
- LNR-IUDs
- Others
Treatment Type:
- Hormonal Therapy
- Pain Management
Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Drugstores
- e-Commerce
Access Exclusive Market Insights – Purchase Now!
https://www.futuremarketinsights.com/checkout/3870
Author
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5,000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
